Evidence map›Paper›PMID 29133566›Full record

Trial reportAntimicrobial agents and chemotherapy2018

Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.

Thomas P Lodise, John Bosso, Colleen Kelly, Paul J Williams, James R Lane, David B Huang

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection model.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Thomas P LodiseAlbany College of Pharmacy and Health Sciences, Albany, New York, USA thomas.lodise@acphs.edu.
John BossoMedical University of South Carolina College of Pharmacy, Charleston, South Carolina, USA.
Colleen KellyMotif BioSciences, Inc., New York, New York, USA.
Paul J WilliamsTrials by Design, LLC, Stockton, California, USA.
James R LaneTrials by Design, LLC, Stockton, California, USA.
David B HuangMotif BioSciences, Inc., New York, New York, USA.
Motif BioSciences (United States) · USAlbany College of Pharmacy and Health Sciences · USMedical University of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iclaprim is a bacterial dihydrofolate reductase inhibitor that is currently being evaluated in two phase 3 trials for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Prior animal infection model studies suggest that the pharmacokinetic/pharmacodynamic (PK/PD) drivers for efficacy are area under the concentration-time curve from 0 to 24 h at steady state (AUC

Indexed as

Models, StatisticalAdultAgedAnti-Bacterial AgentsArea Under CurveDouble-Blind MethodDrug Administration ScheduleDrug Dosage CalculationsFemaleGram-Positive Bacterial InfectionsHumansMaleMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMiddle AgedMonte Carlo MethodAnti-Bacterial AgentsiclaprimPyrimidinesiclaprimMonte Carlo simulationPDPK

Identifiers

PMID29133566
PMCPMC5786772
OpenAlexW2769151879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.